Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

There are some signs of selling into the strength especially in technology names.

Juno Therapeutics To Highlight New Advances In CD19- And BCMA-Targeted CAR T Therapy At ASH

Juno Therapeutics To Highlight New Advances In CD19- And BCMA-Targeted CAR T Therapy At ASH

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that 15 abstracts detailing updated clinical and...

Juno Therapeutics To Report Third Quarter 2017 Financial Results On Wednesday, November 1

Juno Therapeutics To Report Third Quarter 2017 Financial Results On Wednesday, November 1

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017, after the close of U.

How to Make Money Like Amazon Billionaire Jeff Bezos

How to Make Money Like Amazon Billionaire Jeff Bezos

Founding a company that all but rules the world isn't the only way to make a fortune.

Juno Therapeutics Closes Follow-on Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

Juno Therapeutics Closes Follow-on Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on public offering of 7,015,000 shares...

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

The FDA on Thursday issued a safety announcement saying Intercept's liver disease treatment Ocaliva is being dosed incorrectly in some patients.

Juno Therapeutics Prices $250 Million Follow-on Offering

Juno Therapeutics Prices $250 Million Follow-on Offering

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,100,000 shares...

Juno Therapeutics Opens New Headquarters And Research Center

Juno Therapeutics Opens New Headquarters And Research Center

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research facility, located in the...

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.

Juno Therapeutics Launches Follow-on Offering

Juno Therapeutics Launches Follow-on Offering

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the launch of a proposed follow-on public offering of $225...

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Following the lead of more than 400 CEOs across the nation, life science executives penned an open letter to President Trump urging him to step back from his DACA decision.

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Juno Therapeutics To Present At September 2017 Investor Conferences

Juno Therapeutics To Present At September 2017 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in September.

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

I've cut a few positions and haven't made any notable buys today.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Here's what you need to know now for Tuesday, August 29.

JUNO: Insiders vs. Shorts

JUNO: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/15/2017 settlement date, and Juno Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 13.63 "days to cover" versus the median component at 5.20. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics stock was upgraded at Wedbush as Gilead's proposed deal for Kite Pharma raises awareness of Juno's treatments.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Kite Soars on Sale to Gilead - Biotech Movers

Kite Soars on Sale to Gilead - Biotech Movers

The Santa Monica, Calif.-based immunotherapy firm agreed to sell to Gilead Sciences for $180 per share.

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

Insiders Buy the Holdings of FYC ETF

Insiders Buy the Holdings of FYC ETF

A look at the weighted underlying holdings of the First Trust Small Cap Growth AlphaDEX Fund (FYC) shows an impressive 10.2% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Juno Therapeutics Inc , which makes up 0.48% of the First Trust Small Cap Growth AlphaDEX Fund (FYC), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Jim Cramer is bullish on Novartis AG, Sirius XM Radio, Coupa Software and Juno Therapeutics.

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.

Juno Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference

Juno Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2017 Wedbush PacGrow Healthcare Conference at 3:40 p.

Juno Therapeutics Reports Second Quarter 2017 Financial Results

Juno Therapeutics Reports Second Quarter 2017 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the second quarter...

Juno Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3

Juno Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2017 on Thursday, August 3, 2017, after the close of U.

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

Here's what moving in the world of Biotech